{
  "trial_id": "NCT01187459",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "between 8-18 years of age, and have been in remission for at least 4 weeks as indicated by a PCDAI <10.",
      "label": "met"
    },
    {
      "criterion": "assigned without bias to a dose group",
      "label": "met"
    },
    {
      "criterion": "one-hour fasting blood sample and a spot urine collection will be collected, a PCDAI will be administered, and patients will complete a food frequency questionnaire (FFQ) that will include information on Vitamin D and calcium supplement use (including dose and duration) as well as a lifestyle and demographic questionnaire.",
      "label": "met"
    },
    {
      "criterion": "Treatment Visit: One-hour fasting blood and spot urine will be collected and the PCDAI will be administered at baseline, 3 months (+/- 1 week), and 6 months (+/- 1 week) after baseline.",
      "label": "met"
    },
    {
      "criterion": "25OHD concentrations are thought to stabilize after 8 weeks of supplementation at a constant dose.",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "taking corticosteroids, or taking more than 400 IU Vitamin D at enrollment",
      "label": "not_met"
    },
    {
      "criterion": "occurrence of adverse events that are judged to be severe enough for discontinuation.",
      "label": "unknown"
    }
  ],
  "notes": "The patient has a confirmed diagnosis of Paget's Disease of Bone and is starting Bisphosphonate therapy.",
  "_meta": {
    "topic_id": "74",
    "trial_id": "NCT01187459",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}